PAM
CCCC icon

Panagora Asset Management’s C4 Therapeutics CCCC Stock Holding History

Panagora Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Buy
264,947
+178,187
+205% +$609K ﹤0.01% 711
2026
Q1 		$228K Buy
+86,760
New +$204K ﹤0.01% 1057
2023
Q2 		– Sell
-107,891
Closed -$339K – 1291
2023
Q1 		$339K Buy
+107,891
New +$635K ﹤0.01% 1229

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Panagora Asset Management's CCCC Position: Q2 2026 in Review

Panagora Asset Management increased its C4 Therapeutics (CCCC) stake by 205% in Q2 2026, buying an estimated $609K and bringing the position to 264,947 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #711.

Panagora Asset Management first reported a position in CCCC in Q1 2023 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Panagora Asset Management held 264,947 shares of C4 Therapeutics worth $1.24M as of Q2 2026.
  • Panagora Asset Management bought 178,187 C4 Therapeutics shares in Q2 2026, an estimated $609K.
  • C4 Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #711 holding.
  • Panagora Asset Management first reported a position in C4 Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.